Alembic reports revenue for Q1 FY23 Rs. 1262 Cr.

ENPNewswire-August 5, 2022--Alembic reports revenue for Q1 FY23 Rs. 1262 Cr.

(C)2022 ENPublishing - http://www.enpublishing.co.uk

Release date- 04082022 - Vadodara - Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30 1 h June, 2022

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said 'India Branded Business continues to deliver robust numbers in 01. India Business . will witness market outperforming growth across most of the products and therapy areas in current year.'

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said 'It was tough quarter with significant price erosion in the US market, we also charged off a non-recurring expense of Rs. 115 Cr.'

Profit before tax for the quarter is Rs. 47 Cr. before charging off the above nonrecurring expense.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures. and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT